Dr. Hendifar on the HALO-202 Study in Metastatic Pancreatic Ductal Adenocarcinoma

Andrew E. Hendifar, MD
Published: Thursday, Jun 29, 2017



Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

HALO-202 is phase II study that randomized previously untreated patients with metastatic pancreatic ductal adenocarcinoma to PEGPH20 in addition to standard gemcitabine and abraxane versus standard gemcitabine and abraxane alone.

<<< View more from the 2017 World Congress on GI Cancer


Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

HALO-202 is phase II study that randomized previously untreated patients with metastatic pancreatic ductal adenocarcinoma to PEGPH20 in addition to standard gemcitabine and abraxane versus standard gemcitabine and abraxane alone.

<<< View more from the 2017 World Congress on GI Cancer



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor BoardMar 31, 20182.0
Publication Bottom Border
Border Publication
x